|
186. |
Greve, J., Kinaciyan, T.+, Maurer, M., Dillenburger, B., Recke, A., and Schöffl, C.: Expert consensus on prophylactic treatment of hereditary angioedema. Allergo J. 2022: 31; 233-242. IF: N/A |
r.186de
|
186. |
Greve, J., Kinaciyan, T.+, Maurer, M., Dillenburger, B., Recke, A., and Schöffl, C.: Expert consensus on prophylactic treatment of hereditary angioedema. Allergo J. 2022: 31; 233-242. IF: N/A |
r.186
|
177. |
Maurer, M.+, Aberer, W., Caballero, T., Bouillet, L., Grumach, A. S., Botha, J., Andresen, I., and Longhurst, H. J. for the IOS study group: the icatibant outcome survey: 10 years of experience with icatibant for patients with hereditary angioedema. Clin. Exp. Allergy 2022: 52; 1048-1058. IF: 6.10 |
r.177
|
440. |
Farkas, H., Stobiecki, M., Peter, J., Kinaciyan, T., Maurer, M., Aygören-Pürsün, E., Kiani-Alikhan, S., Wu, A., Reshef, A., Bygum, A., Fain, O., Hagin, D., Huissoon, A., Jeseňák, M., Lindsay, K., Grivcheva Panovska, V., Smith, W., Steiner, U. C., Zubrinich, C., Best, J. M., Cornprobst, M., Dix, D., Dobo, S. M., Iocca, H. A., Murray, S. C., Nagy, E., Nagy, E., and Sheridan, W. P.+: Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin. Transl. Allergy 2021: 11; e12035. IF: 5.66 |
o.440
| 434. | Zuraw, B., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Christiansen, S. C., Jacobs, J. S., Sitz, K. V., Gower, R. G., Gagnon, R., Wedner, J., Kinaciyan, T., Hakl, R., Hanzliková, J., Anderson, J. T., McNeil, D. L., Fritz, S. B., Yang, W., H., Tachdjian, R., Busse, P. J., Craig, T. J., Li, H., Farkas, H., Best, J., M., Clemons, D., Cornpropst, M., Dobo, S. M., Iocca, H. A., Kargl, D., Nagy, E., Murray, S. C., Collis, P., Sheridan, W. P.+, Maurer, M.*, and Riedl, M. A.*: Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J. Allergy Clin. Immunol. 2021: 148; 164-172. IF: 14.29 |
o.434
| 426. | Lumry, W. R.+, Weller, K., Magerl, M., Banerji, A., Longhurst, H. J., Riedl, M. A., Lewis, H. B., Lu, P., Devercelli, G., Jain, G., and Maurer, M.: Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy 2021: 76; 1188-1198. IF: 14.71 |
o.426
| 404. | Riedl, M. A.+, Maurer, M., Bernstein, J. A., Banerji, A., Longhurst, H. J., Henry Li, H., Lu, P., Hao, J., Juethner, S., and Lumry, W. R.: Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy 2020: 75; 2879-2887. IF: 13.15 |
o.404
| 390. | Vatsiou, S., Zamanakou, M., Loules, G., Psarros, F., Parsopoulou, F., Csuka, D., Valerieva, A., Staevska, M., Porebski, G., Obtulowicz, K., Magerl, M., Maurer, M., Speletas, M., Farkas, H., and Germenis, A. E.+: A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. Allergol. Int. 2020: 69; 443-449. IF: 5.84 |
o.390
| 234 | Longhurst, H. J.+, Aberer, W., Bouillet, L., Caballero, T., Maurer, M. Fabien, V., Zanichelli, A.: The icatibant outcome survey: treatment of laryngeal angioedema attacks. Eur. J. Emerg. Med. 2016: 23; 224-227. IF: 2.02 |
| 225 | Speletas, M., Szilagyi, A., Csuka, D., Koutsostathis, N., Psarros, F., Moldovan, D., Magerl, M., Kompoti, M., Varga, L., Maurer, M. Farkas, H., and Germenis, A. E.+: F12-46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. Allergy 2015: 70; 1661-1664. IF: 6.33 |